Teva‘s share price is up by more than 8% on the Tel Aviv Stock Exchange after the Israeli pharmaceutical company Named its new Kare Schultz as President and Chief Executive Officer.
Kare Schultz, 56, will succeed Dr. Yitzhak Peterburg, who will continue to serve as Interim Chief Executive Officer until Schultz joins the Company. Today’s leadership announcement represents the successful completion of the global search process to identify the best leader for the Company and was executed by the Teva Board of Directors, with the assistance of Heidrick & Struggles. Mr. Schultz will be relocating to Israel and based out of the Company’s Petah Tikva headquarters.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Schultz will be relocating to Israel and based out of the Company’s Petah Tikva headquarters.
Kare Schultz brings nearly 30-year career in global pharmaceutical and healthcare companies. Schultz has developed a unique perspective overseeing generic and specialty drug
In its announcement, Teva emphasizes the wide experience of Schultz. He has developed a unique perspective overseeing generic and specialty drug portfolios while managing complex business operations around the world.
Since 2015 he served as the President and Chief Executive Officer of H. Lundbeck A/S, where he is credited with leading significant restructuring initiatives and launching a robust turnaround strategy focused on driving a sustainable global cost structure and operational model.
As a result of his leadership, the company is on track to achieve all-time high revenue and earnings.
Prior to his role at H. Lundbeck A/S, Shultz served as Chief Operating Officer of Novo Nordisk, where he had a key role in building the company into one of the world’s best-performing drugmakers and implementing a metrics-focused approach to the company’s operations.
“With extensive global pharmaceutical experience, a strong track record executing corporate turnaround strategies, driving growth and international expansion at low incremental cost and delivering on promises to shareholders, as well as a commitment to a culture of compliance, Kåre is the right leader to take Teva to the next level,” said Dr. Sol J. Barer, Chairman of Teva’s Board of Directors.
“Kare has deep insight into the global pharmaceutical industry and a keen knowledge of the generic and specialty drug markets. His proven strategic, financial and operational capabilities and his strong commitment to growth will enhance value for all stakeholders and position Teva for long-term success. He brings a strong sense of corporate citizenship, and his disciplined commitment to excellence makes him a clear professional and cultural fit with our company. We are pleased to welcome a world-class leader of Kare’s stature to Teva and look forward to working closely with him to build the Teva of the future for shareholders, employees and patients around the world.”
Kare Schultz said, “I am honored to join Teva, an iconic company that I have long admired during my career. What drew me to Teva, and what makes Teva different from its peers, is its unique commitment to growing an extensive global reach while continuing to provide new and high-quality treatments for patients and an innovative culture for its employees. I am proud to be joining a company that helps millions of patients around the world on a daily basis with its broad range of generic and specialty drugs and solutions. I look forward to working closely with the entire team at Teva to build a future of success for the Company and its stakeholders.”
Dr. Barer continued, “On behalf of the Board, I want to thank Yitzhak for taking on the role of interim CEO during this critical period. Yitzhak’s leadership and insight have greatly helped the Company remain focused on the execution of its key strategic priorities.”
Dr. Yitzhak Peterburg said, “We are delivering on the commitments we have made over the last several months. We are optimizing our operations and geographical footprint while focusing our resources on the specialty and generics pipeline assets that offer the most attractive return on investment. In addition, we are on course to hit our target of generating at least $2 billion from the sale of non-core assets, which we will use to strengthen Teva’s balance sheet. It is a privilege to lead Teva and I look forward to continuing to do so during this time, and will work with Kåre to ensure a seamless transition once he joins.”
